<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449135</url>
  </required_header>
  <id_info>
    <org_study_id>Nano drug pancreatic cancer</org_study_id>
    <nct_id>NCT02449135</nct_id>
  </id_info>
  <brief_title>Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma</brief_title>
  <official_title>Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuda Cancer Hospital, Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fuda Cancer Hospital, Guangzhou</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of nano drug interventional
      therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is
      made by mixing Gemzar® with Compound Glycyrrhizin Injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will
      document for the first time the safety and the short and long term efficacy of nano drug
      interventional therapy using digital subtraction angiography（DSA）for pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>interventional therapy</intervention_name>
    <description>Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18-80

          2. Karnofsky performance status &gt;60

          3. Diagnosis of pancreatic cancer based on histology or the current accepted radiological
             measures.

          4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ

          5. Will receive interventional therapy

          6. Life expectancy: Greater than 3 months

          7. Patients' routine blood test, liver function and kidney function have no obvious
             abnormalities

          8. Ability to understand the study protocol and a willingness to sign a written informed
             consent document

        Exclusion Criteria:

          1. Patients with other primary tumor except pancreatic cancer

          2. History of coagulation disorders or anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lizhi Niu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuda Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Li, Master</last_name>
    <phone>+86-15521338517</phone>
    <email>liyuan.lily@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xianghao Piao, PhD</last_name>
    <phone>+86-18922210320</phone>
    <email>spacepiao@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central laboratory in Fuda cancer hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jibing Chen, PhD</last_name>
      <phone>+86-18903068207</phone>
      <email>jibingchen398@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Piao+xianghao</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Niu L, Chen J, Yao F, Zhou L, Zhang C, Wen W, Bi X, Hu Y, Piao X, Jiang F, Zeng J, Liu W, Li J, He L, Mu F, Zuo J, Xu K. Percutaneous cryoablation for stage IV lung cancer: a retrospective analysis. Cryobiology. 2013 Oct;67(2):151-5. doi: 10.1016/j.cryobiol.2013.06.005. Epub 2013 Jun 24.</citation>
    <PMID>23806858</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2015</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Nano drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

